试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Seagen Inc.
- 入组人数
- 322
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumorsgastroesophageal junction [GEJ] carcinoma, Non-small cell lung cancer (NSCLC), Gastric cancer, Cervical cancer, Ovarian cancer, Endometrial cancer, Malignant ovarian GCT with the exception of pure teratomas, Malignant testicular germ cell tumor (GCT) with the exception of pure teratomas, Gastroesophageal junction carcinoma, Malignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS)MedDRA version: 21.1Level: LLTClassification code: 10043338Term: Testicular malignant germ cell tumor NOS Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: HLTClassification code: 10033222Term: Ovarian germ cell neoplasms malignant Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10066354Term: Adenocarcinoma of the gastroesophageal junction Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10073060Term: Extragonadal primary germ cell tumor Class: 10029104CTIS2022-500094-14-00Seagen Inc.254
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participantsCTIS2024-512939-67-00Mindstate Design Labs Inc.68
招募中
1 期
A Phase 1 Study of SEA-CD70 in Myeloid MalignanciesCTIS2023-506945-42-00Seagen Inc.140
招募中
1 期
A Study of SGN-B7H4V in Advanced Solid Tumorson-small cell lung cancer (squamous cell carcinoma [SqCC]), HER2-negative, HR-positive breast cancer, Adenoid cystic carcinoma (ACC) of the head and neck, Triple-negative breast cancer, High-grade serous epithelial ovarian cancer, Fallopian tube cancer, Endometrial carcinoma, Primary peritoneal cancer, Cholangiocarcinoma, Gallbladder carcinomaMedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 24.0Level: PTClassification code: 10085481Term: Hormone receptor positive HER2 negative breast cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10008593Term: Cholangiocarcinoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10017614Term: Gallbladder cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061328Term: Ovarian epithelial cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10053231Term: Adenoid cystic carcinoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10016180Term: Fallopian tube cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10061269Term: Malignant peritoneal neoplasm Class: 100000004864CTIS2023-503389-22-00Seagen Inc.400
招募中
1 期
A Study of SGN-BB228 in Advanced Melanoma and Other Solid TumorsCTIS2022-502348-11-00Seagen Inc.275